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The upcoming 11th revision of the International Classification of Diseases and Related Health Problems 
(ICD) of the World Health Organization (WHO) offers a unique opportunity to improve the 
representation of painful disorders. For this purpose, the International Association for the Study of 
Pain (IASP) has convened an interdisciplinary task force of pain specialists. Here we present the case 
for a reclassification of nervous system lesions or diseases associated with persistent or recurrent pain 
for ≥ 3 months. The new classification lists the most common conditions of peripheral neuropathic 
pain: trigeminal neuralgia, peripheral nerve injury, painful polyneuropathy, postherpetic neuralgia, 
and painful radiculopathy. Conditions of central neuropathic pain include pain caused by spinal cord 
or brain injury, post-stroke pain, and pain associated with multiple sclerosis. Diseases not explicitly 
mentioned in the classification are automatically captured in the residual categories of ICD-11. These 
conditions are either insufficiently defined or missing in the current version of the ICD despite their 
prevalence and clinical importance. We provide the short definitions of diagnostic entities for which 
we submitted more detailed content models to the WHO. Definitions and content models were 
established in collaboration with the Classification Committee of the IASP’s Neuropathic Pain Special 
Interest Group (NeuPSIG). Up to 10% of the general population experience neuropathic pain. The 
majority of these patients do not receive satisfactory relief with existing treatments. A precise 
classification of chronic neuropathic pain in ICD-11 is necessary to document adequately this public 
health need and the therapeutic challenges related to chronic neuropathic pain. 
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1. Neuropathic pain 
Lesions or diseases involving the somatosensory nervous system may paradoxically not only lead to a 
loss of function but also to increased pain sensitivity and spontaneous pain. This neuropathic pain is 
usually chronic, i.e., it either persists continuously or manifests with recurrent painful episodes. Pain 
may result from etiologically diverse disorders affecting the peripheral or the central nervous system. 
The cause can be a metabolic disease, e.g., diabetic neuropathy, a neurodegenerative, vascular or 
autoimmune condition, a tumor, trauma, infection, exposure to toxins or a hereditary disease. Chronic 
pain also occurs in neurological conditions of unknown etiology, e.g., idiopathic neuropathies.5 The 
mechanistic underpinnings of pain hypersensitivity and spontaneous pain in these conditions are 
complex, and their relationship to the underlying pathological disease process often remains unclear. 
On the other hand, differences in pain phenotypes offer an opportunity to distinguish pain syndromes 
clinically.1,9,30 Neurophysiological investigations may reveal some mechanistic clues, e.g., activity 
increases in somatosensory nerve fibers or changes in the endogenous control of pain.14,17 However, a 
lack of suitable noninvasive tests usually precludes an in-depth evaluation of active pain mechanisms 
in patients. Although imaging studies and quantitative sensory tests help elucidate important 
pathophysiological aspects of pain in patients, current knowledge of neuropathic pain mechanisms is 
based largely on animal models. 
Chronic neuropathic pain is a major factor contributing to the global burden of disease.21 Its 
prevalence ranges between 6.9% and 10% of the general population.28 How strongly pain is associated 
with a particular neurological disease varies. Pain may be the most prominent or sole disease 
manifestation as, e.g., in postherpetic neuralgia, or it may occur only in a subgroup of patients with 
the same disease as, e.g., in chemotherapy-induced peripheral neuropathies. Even among patients 
with the same underlying cause of neuropathic pain, painful symptoms and signs usually differ.4 
However, when present, neuropathic pain frequently causes major suffering and disability. 
Therapeutic management is challenging. Medications recommended as first-line treatments provide 



































































A suspected diagnosis of neuropathic pain requires specific investigations to ascertain that the 
pain originates in the nervous system. The distribution of pain must correspond to the underlying 
lesion or disease of the somatosensory nervous system. The neuroanatomical relation to the 
underlying cause must still be recognizable even if pain is not felt in the entire innervation territory of 
an affected peripheral nerve or root, or the somatotopic representation corresponding to a lesion or 
disease of the central nervous system, or if pain extends somewhat outside these boundaries. 
Objective signs of a sensory disorder in the distribution of pain increase diagnostic certainty. These 
signs may indicate a sensory deficit or exaggerated responses to normally painful (hyperalgesia) or 
painless stimuli (allodynia). The definite diagnosis of neuropathic pain requires demonstration of the 
cause, e.g., neurophysiological tests confirming a peripheral neuropathy or imaging results showing 
the involvement of somatosensory fiber tracts after spinal cord injury.6,10,25 Neuropathic pain also 
requires specific treatment, involving both pharmacological and nonpharmacological approaches.8,11 
Evidence of high or moderate quality supports the use of gabapentin, pregabalin and inhibitors of 
serotonin, noradrenalin uptake and tricyclic antidepressants as medications of first choice. Dermal 
patches releasing lidocaine or capsaicin and subcutaneous injection of botulinum toxin offer topical 
treatment options. Opioids should be reserved for patients not responding to therapeutic alternatives 
with a lower risk of adverse effects.11 Analgesics such as nonsteroidal anti-inflammatory drugs have no 
proven efficacy against pain of neuropathic origin.18,29 These particular requirements for evaluation 
and treatment call for an accurate representation of neuropathic pain in diagnostic classifications of 
the relevant clinical conditions.  
 
2. Shortcomings of ICD-10 
A structured classification of conditions associated with neuropathic pain is critically needed.12 To date, 
the International Classification of Headache Disorders (ICHD) is the only disease classification providing 




































































Despite its clinical and economic significance, neuropathic pain is not adequately represented 
in the current version of the International Classification of Diseases and Related Health Problems (ICD) 
of the World Health Organization (WHO). The ICD is the most widely used source for diagnostic codes 
and the standard instrument for disease classification in clinical practice, epidemiology and health 
management.31 The ICD organizes diseases and clinical syndromes by etiology, affected organ or body 
region. In the current version of the ICD (ICD-10), painful conditions that do not fit this scheme can be 
classified as acute (R52.0) or chronic pain (R52.2), with a separate code for chronic “intractable” pain 
(R52.1). These codes can be combined with neurological diagnoses, e.g., diabetic polyneuropathy 
(G63.2*). The asterisk behind the code indicates a clinical syndrome in need of another etiological 
code, marked by a dagger. In this example, type 2 diabetes mellitus with neurological complications 
(E11.4†) would be a suitable specification. Thus, 3 codes are required to fully describe painful diabetic 
polyneuropathy, one of the most common manifestations of neuropathic pain that affects up to 30% 
of patients with type 2 diabetes.3 
There are very few explicit references to conditions of neuropathic pain in ICD-10. They include 
trigeminal neuralgia (G50.0), postzoster neuralgia (G53.0* B02.2†) and phantom limb syndrome with 
pain (G54.6). The code for postzoster neuralgia, better known as postherpetic neuralgia, applies only 
if the disorder involves a cranial nerve, although thoracic nerve roots are far more commonly affected 
by the disease.24 Hereditary neuropathies that are predominantly characterized by painful symptoms 
or signs are not listed at all or incorrectly classified. For example, erythromelalgia is designated as 
peripheral vascular disease (I73.8), because painful episodes associated with the disease are 
accompanied by an erythema. A hereditary variant of the disease, in which intense pain, not reddening, 
is the leading symptom, remains unspecified.7 
The complexity of ICD-10 codes, and the incomplete or inaccurate coverage of relevant clinical 
conditions, risk underreporting of chronic pain. This has practical consequences for clinicians, hospitals 
and other health care providers. Underreporting also hinders efficient resource management by 



































































of opioid abuse in North America illustrates the importance of a reliable classification of chronic pain 
to enable the monitoring of safe and effective analgesics use in non-cancer pain, including pain of 
neuropathic origin.13 
 
3. The IASP Task Force Initiative for the Classification of Chronic Pain in the ICD 
To generate a systematic and improved classification of conditions associated with clinically relevant 
pain and to ensure representation of these diagnoses in the upcoming revision of the ICD, the 
International Association for the Study of Pain (IASP) established a Task Force that works in close 
cooperation with WHO representatives.27 The classification is dedicated exclusively to chronic pain 
syndromes, defined as persistent or recurrent pain lasting ≥ 3 months. As we have previously outlined, 
conditions of neuropathic pain are divided into two broad categories for peripheral or central nervous 
diseases. Diseases not explicitly listed in the classification will be captured in residual categories.27 
During the process of drafting and editing the definitions of individual diseases and detailed content 
models of neuropathic pain, the Task Force conferred with the Classification Committee of the IASP’s 
Neuropathic Pain Special Interest Group (NeuPSIG). Content models underwent initial field testing in 
Australia, Germany, Japan, and Norway. Revised models were subjected to further testing on the IASP 
website. We will report the results of these field tests separately. Overall, diagnostic utility and 
specificity of the diagnostic criteria were ranked highly. A version for preparing implementation of ICD-
11 was released by the WHO in June 2018.32 The complete edition will be submitted to the WHO’s 
Executive Board in January and the World Health Assembly in May 2019. Following endorsement, 
member states are expected to report health statistics according to ICD-11 from 2022 onward. 
 
4. The classification of chronic neuropathic pain 
Some conditions of persistent neuropathic pain produce distinct symptoms that would allow 



































































characterized by a pain distribution in one or more branches of the 5th cranial nerve, abrupt pain 
paroxysms, and provocation of these pain attacks by normally innocuous mechanical stimuli or 
orofacial movements. Periods of remission vary, but the neuralgia never disappears completely.6,15 
Similarly, pain associated with polyneuropathy caused by type 2 diabetes or central pain after spinal 
cord injury usually persists so that it may seem unnecessary to wait 3 months before diagnosing 
chronic neuropathic pain.3,23 Nonetheless, in the absence of objective markers delineating acute and 
chronic phases of pain, the arbitrary definition of 3 months was chosen because it provides for clear 
operationalization in line with widely used research criteria and subject enrolment in analgesic 
treatment trials.26 
The proposed classification differentiates neuropathic pain of peripheral and central origin.16 
It comprises nine common conditions associated with persistent or recurrent pain (Fig. 1 and 
supplementary Table 1). Short definitions of these conditions are listed below. These definitions are 
part of more detailed content models included in the so-called foundation layer of ICD-11. The models 
provide minimum criteria of possible neuropathic pain and describe investigations that support a 
definitive diagnosis.6,10 They also contain extension codes for pain severity (combining intensity, 
distress and disability), temporal characteristics and psychological or social factors,26 as well as a link 
to the International Classification of Functioning (ICF).19,33  
------------ 
Insert Figure 1 about here 
------------ 
4.1. Chronic neuropathic pain 
Chronic neuropathic pain is chronic pain caused by a lesion or disease of the somatosensory nervous 
system.16 The pain may be spontaneous or evoked, as an increased response to a painful stimulus 
(hyperalgesia) or a painful response to a normally nonpainful stimulus (allodynia). The diagnosis of 
chronic neuropathic pain requires a history of nervous system injury or disease and a 



































































and positive sensory symptoms or signs (e.g., allodynia or hyperalgesia) indicating the involvement of 
the somatosensory nervous system must be compatible with the innervation territory of the affected 
nervous structure. These criteria apply to all diagnostic entities of chronic neuropathic pain.  
 
4.1.1 Chronic peripheral neuropathic pain 
Chronic peripheral neuropathic pain is chronic pain caused by a lesion or disease of the peripheral 
somatosensory nervous system. 
 
4.1.1.1 Trigeminal neuralgia 
Trigeminal neuralgia is a manifestation of orofacial neuropathic pain restricted to one or more divisions 
of the trigeminal nerve. The pain is recurrent, abrupt in onset and termination, triggered by innocuous 
stimuli and typically compared to an electric shock or described as shooting or stabbing. Some patients 
experience continuous pain between these painful paroxysms. 
The diagnosis comprises idiopathic trigeminal neuralgia, classical neuralgia produced by 
vascular compression of the trigeminal nerve, and secondary neuralgias caused by a tumor or cyst at 
the cerebellopontine angle, or multiple sclerosis.6 As for other conditions of chronic neuropathic pain, 
the detailed content model will include a discussion of the etiology. 
 
4.1.1.2 Chronic neuropathic pain after peripheral nerve injury 
Chronic neuropathic pain after peripheral nerve injury is persistent or recurrent neuropathic pain 
caused by a peripheral nerve lesion. History of a plausible nerve trauma, pain onset in temporal 
relation to the trauma, and pain distribution within the innervation territory of a peripheral nerve (or 



































































compatible with the innervation territory of the affected nerve (or nerves). Formation of a neuroma 
may lead to pain at the lesion site. 
Consistent with the new concept of ‘multiple parenting’ in ICD-11 (Fig. 1), the diagnosis of chronic 
neuropathic pain after peripheral nerve injury is also listed in the section on posttraumatic and 
postsurgical pain.22 However, the content model for the diagnosis is stored in the foundation layer of 
ICD-11. This hierarchical structure of the classification allows for multiple referencing of a content 
model without duplicating the diagnosis. 
 
4.1.1.3 Painful polyneuropathy 
Chronic pain occurs in polyneuropathies caused by metabolic, autoimmune, familial or infectious 
diseases, exposure to environmental or occupational toxins, or treatment with a neurotoxic drug. 
Chronic pain also occurs in polyneuropathies of unknown etiology. Pain may be the initial symptom of 
a neuropathy or develop over the course of the disease (Box 1). Negative and positive sensory 
symptoms or signs must be compatible with the anatomical distribution pattern of the 
polyneuropathy. Chemotherapy-induced peripheral neuropathy is one form of painful polyneuropathy 
included in the classification of chronic cancer-related pain.2 
 
4.1.1.4 Postherpetic neuralgia 
Postherpetic neuralgia is defined as pain persisting for ≥ 3 months following the onset or healing of 
herpes zoster. The innervation territory of the first (ophthalmic) branch of the trigeminal nerve and 
thoracic dermatomes are the locations most frequently affected by chronic pain after herpes zoster. 
Postherpetic neuralgia may emerge in continuation of the acute pain associated with the skin rash or 
develop after a painless interval. Negative and positive sensory symptoms or signs must be compatible 




































































4.1.1.5 Painful radiculopathy 
Chronic painful radiculopathy is persistent or recurrent pain caused by a lesion or disease involving the 
cervical, thoracic, lumbar or sacral nerve roots. Degenerative changes of the spinal column including 
ligaments and intervertebral discs are the most frequent cause, but painful radiculopathy may also 
result from trauma, tumor or neoplastic meningitis, from infections, hemorrhage or ischemia, diabetes 
mellitus, rheumatoid arthritis, or from an iatrogenic lesion, e.g., during injection therapy or surgery. 
Pain within the affected dermatomes (radicular pain) is required for the diagnosis. The pain may be 
spontaneous but is typically exacerbated or provoked by taking or maintaining a certain body position, 
or during movement. Negative and positive sensory symptoms or signs must be compatible with the 
innervation territory of the affected nerve root (or roots). Musculoskeletal pain associated with painful 
radiculopathy should be classified separately.20 
 
4.1.1.6 Other specified, and unspecified chronic peripheral neuropathic pain 
ICD-11 will contain a residual category for other specified conditions of chronic peripheral neuropathic 
pain that are not covered by the disease codes listed above, e.g., chronic neuropathic pain caused by 
a carpal tunnel syndrome. An additional category for unspecified conditions will provide for the 
classification of disorders for which insufficient information is available to assign a more precise 
diagnosis. 
 
4.1.2 Chronic central neuropathic pain 
Chronic central neuropathic pain is chronic pain caused by a lesion or disease of the central 




































































4.1.2.1 Chronic central neuropathic pain associated with spinal cord injury 
Chronic central neuropathic pain associated with spinal cord injury is caused by a lesion or disease of 
the somatosensory pathways in the spinal cord. The definition of spinal cord injury comprises 
impairments of spinal cord function resulting from external force or a disease process. The pain may 
be spontaneous or evoked, as an increased response to a painful stimulus (hyperalgesia) or a painful 
response to a normally nonpainful stimulus (allodynia). The diagnosis requires a history of spinal cord 
lesion or disease and a neuroanatomically plausible distribution of the pain, i.e. pain felt in 
dermatomes at or below the level of injury in areas with sensory disturbance (Box 1). This cause of 
central neuropathic pain is also included in the classification of chronic postsurgical and posttraumatic 
pain.22 
 
4.1.2.2 Chronic central neuropathic pain associated with brain injury 
Chronic central neuropathic pain associated with brain injury is caused by a lesion or disease of the 
somatosensory cortex, connected brain regions or associated pathways in the brain. History of a 
plausible brain trauma, pain onset in temporal relation to the trauma, and a pain distribution that is 
neuroanatomically plausible are required for the diagnosis. Negative or positive sensory symptoms or 
signs indicating the involvement of the brain must be present in the body region corresponding to the 
brain injury. See also the classification of chronic postsurgical and posttraumatic pain.22 
 
4.1.2.3 Chronic central post-stroke pain 
Chronic central post-stroke pain is caused by a cerebrovascular lesion, infarct or hemorrhage, of the 
brain or brainstem. The pain may be spontaneous or evoked, as an increased response to a painful 
stimulus (hyperalgesia) or a painful response to a normally nonpainful stimulus (allodynia). The 
diagnosis of central post-stroke pain requires a history of stroke and a neuroanatomically plausible 



































































affected by the stroke. The pain may affect half of the body or a smaller region. Negative or positive 
sensory symptoms or signs indicating the involvement of the brain must be in the body region affected 
by the stroke. 
 
4.1.2.4 Chronic central neuropathic pain caused by multiple sclerosis 
Chronic central neuropathic pain in multiple sclerosis is caused by a lesion of somatosensory brain 
regions or their connecting pathways. The pain may be spontaneous or evoked, as an increased 
response to a painful stimulus (hyperalgesia) or a painful response to a normally nonpainful stimulus 
(allodynia). The diagnosis requires a history of multiple sclerosis and a neuroanatomically plausible 
distribution of the pain. Negative or positive sensory symptoms or signs indicating the involvement of 
the brain or spinal cord must be present in the area of the body affected by pain. Pain primarily related 
to spasticity should be classified as musculoskeletal pain.20 
 
4.1.2.5 Other specified, and unspecified chronic central neuropathic pain 




Neuropathic pain commonly persists beyond the natural healing process of the underlying disease, e. 
g., in postherpetic neuralgia, or despite treatment directed at the disease cause. Combining a code for 
the underlying disease with the explicit codiagnosis of neuropathic pain has the advantage that for the 
first time, patients with specific treatment needs for their pain will be distinguished from those with a 
painless manifestation of the same neurological disorder. While the neurological diagnosis will guide 



































































for appropriate pain management. Different from previous editions of the ICD, the new codes for 
neuropathic pain will be concise and embedded in a systematic classification of chronic pain. They will 
cover the epidemiologically most relevant conditions and provide clear diagnostic criteria that are 
backed by literature references and suggestions for additional investigations to increase the level of 
diagnostic certainty.  
ICD-11 will include cross-references to other conditions of chronic pain in separate “parent” 
chapters. Examples are painful chemotherapy-induced polyneuropathy, which will be mentioned 
under chronic cancer-related pain,2 or pain after amputation, which will be listed under chronic 
postsurgical and posttraumatic pain.22 Cross-referencing in ICD-11 facilitates the coding of painful 
disorders within the most fitting treatment-relevant category of the classification. 
The proposed classification is a compromise balancing the length of this important division with those 
of 6 other groups of chronic pain conditions, e.g., musculoskeletal and visceral pain. Diseases not 
explicitly listed in the classification will be captured in residual categories for “Other specified chronic 
peripheral neuropathic pain” or “Other specified chronic central neuropathic pain”. 
 
6. Summary and conclusions 
The classification of chronic neuropathic pain represents the first systematic and most comprehensive 
classification to date of common painful neurological disorders. Precise diagnostic criteria and 
literature references are included in the full-content description of the disorders to minimize 
ambiguity. The criteria match the grading system for evidence supporting the diagnosis of neuropathic 
pain in clinical practice and research11. These provisions generate a valuable tool for diagnostic code 
assignment, appropriate allocation of health care services and the collection of epidemiological data. 
Clear definitions combined with a seamless evaluation of the evidence leading to the diagnosis of 
chronic neuropathic pain will facilitate patient identification for enrolment in clinical trials and 
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Box 1. Case vignettes of chronic neuropathic pain 
 
Chronic painful polyneuropathy 
A 56-year old woman with type 2 diabetes mellitus for 2 years complains about pain in the feet which 
started approximately 4 months ago. The pain intensity is 5 to 7 on a scale from 0 to 10. The pain may 
get worse at night or when she is walking. Additionally, she noticed numbness and tingling in the feet. 
The examination reveals a stocking-like distribution of deficits in the sense of touch. The Achilles 
tendon reflex is weak. An electrophysiological examination shows slow conduction in the sural and 
peroneal nerves. The patient has a body mass index of 30. Her fasting blood glucose concentration is 
132 mg/dl, the HbA1 measures 7%. Painful polyneuropathy caused by type 2 diabetes mellitus was 
diagnosed. The treatment plan consisted of improved blood glucose management, medication for 
neuropathic pain, and foot care education. 
 
Chronic central neuropathic pain associated with spinal cord injury 
A 40-year-old man who 5 years ago suffered an incomplete spinal cord injury at the thoracic level 
reports diffuse pain in both legs. He describes an ongoing pain of burning and squeezing character as 
well as sensations of pins and needles. The average pain intensity is 6/10. Additionally, he sometimes 
experiences pain provoked by light touch. These painful sensations developed gradually over the first 
6 months after the injury. On physical examination, he exhibits decreased detection of both 
mechanical and thermal stimuli from dermatome T4 down, hypersensitivity to cold and touch-evoked 
allodynia on the lower legs. The diagnosis was chronic central neuropathic pain associated with spinal 
cord injury. Following referral to a multidisciplinary center for pain therapy, he received 







































































Figure 1. Classification of chronic neuropathic pain in ICD-11. Level 1 and 2 diagnoses are part of ICD-
11 beta32. Specific entities of chronic neuropathic pain are included at the next level. According to the 
new concept of multiple parenting in ICD-11, these entities may be referred to from other divisions of 










































































Figure Click here to download Figure Scholz_Figure1_neuropathic-
pain.tif
Table 1: Prevalence of chronic neuropathic pain 
 
Table 1 
Prevalence of chronic neuropathic pain  
Diagnosis Incidence Prevalence 
Chronic peripheral neuropathic pain   
Trigeminal neuralgia4 4.3–27/100,000 0.16%–0.3% 
Chronic neuropathic pain after 
peripheral nerve injury 
Unknown  
Painful polyneuropathy2  One third of 3.4–7/100,000, which is the 
prevalence of polyneuropathy 
Postherpetic neuralgia6 7%–50% at ≥ 3 months after herpes 
zoster 
 
Painful radiculopathy2 83–486/100,000  
Chronic central neuropathic pain    
Chronic central neuropathic pain 
associated with spinal cord injury1 
 39%–67% after spinal cord injury 
Chronic central neuropathic pain 
associated with brain injury 
Unknown  
Chronic central post-stroke pain3  Approximately 8% after stroke 
Chronic central neuropathic pain 
associated with multiple sclerosis5 
 28% of patients with multiple sclerosis 
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Table 2: Foundation IDs 
 
Entity Foundation ID1 
Chronic neuropathic pain  1170330671 
Chronic peripheral neuropathic pain  425464783 
     Trigeminal neuralgia2 * 1803581281 
     Chronic neuropathic pain after peripheral nerve 
      injury2 
1934323282 
     Chronic painful polyneuropathy 375159195 
     Postherpetic neuralgia * 1797210650 
     Chronic painful radiculopathy 302257973 
     Chronic painful chemotherapy- induced 
     polyneuropathy2  
1299421977 
     Chronic painful radiation-induced neuropathy2  629534369 
Chronic central neuropathic pain 1297540670 
     Chronic central neuropathic pain associated with 
     spinal cord injury2  
869493945 
     Chronic central neuropathic pain associated with 
     brain injury2  
334893123 
     Chronic central post-stroke pain 1221409481 
     Chronic central neuropathic pain associated with 
     multiple sclerosis 
2044099972 
Note: Further sublevels will become available, as the classification is refined.  
 
* Imported from another chapter 
 
1 To locate the entity and its description in the browser: Enter the foundation ID into the search field of 
the ICD-11 Browser (https://icd.who.int/dev11/l-m/en#/) to find the entry for each entity.  
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